Variable frequency drive circuit with overvoltage protection

A variable frequency drive (VFD) circuit includes an input connectable to an AC source, a rectifier to convert an AC power input to a DC power, a DC link to receive DC power from the rectifier and having a DC link voltage thereon, a DC link capacitor bank with one or more capacitors connected to the DC link, and a pre-charge circuit coupled to the DC link capacitor. The pre-charge circuit further includes one or more resistors, one or more pre-charge relays each operable in on and off states to selectively control a current flow through the resistor(s) so as to control an initial pre-charge of the DC link capacitor, and an overvoltage relay operable in on and off states to selectively cut-off a current flow to the DC link capacitor bank, so as to prevent an overvoltage condition in the DC link capacitor bank.

BACKLIGHT ASSEMBLY AND LIQUID CRYSTAL DISPLAY ASSEMBLY

The present invention provides a backlight assembly which includes a plastic frame, the plastic frame, a light guide plate, a light bar and an optical diaphragm group, a side surface of the plastic frame deviating from the reflective sheet is provided with a double-sided adhesive, at least one side frame of the plastic frame is provided with a groove which is disposed at a side surface of the plastic frame opposite to the double-sided adhesive, the double-sided adhesive includes a conductive heat dissipation layer and a double-sided adhesive layer, and a first metal sheet is disposed on a double-sided adhesive layer, located on the groove and contacts the optical diaphragm group and the conductive heat dissipation layer, respectively. The present invention further provides a liquid crystal display assembly. 1. A backlight assembly , comprising a plastic frame , a reflective sheet disposed at a side surface of the plastic frame , a light guide plate disposed in the plastic frame , a light bar disposed in the plastic frame and opposites to a side of the light guide plate and an optical diaphragm group disposed on a side surface of the light guide plate deviating from the reflective sheet , wherein a side surface of the plastic frame deviating from the reflective sheet is provided with a double-sided adhesive , at least one side frame of the plastic frame is provided with a groove which is disposed at a side surface of the plastic frame opposite to the double-sided adhesive and passes through an internal side and an external side of the frame of the plastic frame and a side surface of the frame of the plastic frame opposite to the double-sided adhesive; the double-sided adhesive comprises a conductive heat dissipation layer for conducting static and dissipating heat and a double-sided adhesive layer disposed on both side surfaces of the conductive heat dissipation layer , and a first metal sheet is disposed on a double-sided adhesive layer opposite to the plastic frame ...

Liquid crystal display and backlight module thereof containing functional module and compensation light source

A liquid crystal display and a backlight module thereof are provided. The backlight module includes a backlight source and a light guide plate. The backlight source is disposed at a side surface of the light guide plate. The light guide plate has an accommodation section for accommodating a functional module. The backlight module includes a compensation light source that is disposed on the light guide plate. The accommodation section is located between the backlight source and the compensation light source. The backlight module includes a compensation light source, and the backlight source and the compensation light source are located at two opposite sides of the accommodation section. The compensation light source may compensate for the illumination light in the light guide plate blocked by the functional module, so as to solve the non-uniform display problem of blocking the illumination light from the backlight source by the functional module.

3D printing device and method

A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the ...

Cholesterol-Regulating Complex of SIRT1 and LXR and Methods of Use

A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed.

SYSTEM AND METHOD FOR SINGLE-PHASE AND THREE-PHASE CURRENT DETERMINATION IN POWER CONVERTERS AND INVERTERS

A system and method for capturing current information for a power converter is disclosed. The current monitoring system includes a control system operably connected to a circuit having a plurality of semiconductor switches that are controllable to convert an input power to an output power having a desired voltage and current. The control system includes a PWM signal generator to generate switching signals that control switching of the switches, gate drivers to facilitate switching of the switches, and desaturation circuits to provide overcurrent protection to the switches. The control system further includes a processor that receives voltage data from the desaturation circuits regarding a measured voltage across each of the switches, determines a current through each of the switches based on the voltage across each respective switch, and calculates an input current to the circuit or an output current of the circuit based on the determined currents through the switches. 1. A current monitoring system for capturing current information for a power converter , the current monitoring system comprising:a circuit including a plurality of semiconductor switches being controllable to convert an input power from a source to an output power having a desired voltage and current; and a PWM signal generator configured to generate switching signals to control switching of the plurality of semiconductor switches;', 'a gate driver corresponding to each of the plurality of semiconductor switches and configured to receive the switching signals from the PWM signal generator and produce an amplified high-current drive signal for input to a respective semiconductor switch so as to facilitate efficient switching thereof;', 'a desaturation circuit connected to each gate driver to provide overcurrent protection to a respective semiconductor switch, the desaturation circuit configured to measure a voltage across its respective semiconductor switch; and', receive voltage data from the ...

System and method for additively manufacturing boiler tubes

A method of manufacturing a tube is provided. The method includes: selecting a core pipe having a thickness that is initially less than a desired thickness of the tube; and building-up an outer layer over an exterior surface of the core pipe via additive manufacturing so as to increase the thickness of the core pipe such that the thickness of the core pipe is equal to the desired thickness of the tube.

Compartmented pharmaceutical dosage forms

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Fingerprint scanner

System and method for capacitor fault energy interruption in adjustable speed drives

An adjustable speed drive (ASD) circuit includes a rectifier bridge to convert an AC power input to a DC power, a DC link coupled to the rectifier bridge to receive the DC power, a DC link capacitor bank comprising at least first and second capacitors connected to the DC link, each capacitor having a capacitor voltage thereacross, and a protection circuit including a detection circuit configured to detect a short circuit on one or more of the first and second capacitors of the DC link capacitor bank and generate an action signal upon detection of a short circuit on one or more of the first and second capacitors of the DC link capacitor bank. The ASD circuit also includes an action circuit in operable communication with the detection circuit and configured to cause a short circuit across the DC link upon receiving the action signal from the detection circuit.

Ocular Agent Delivery Systems

This invention is directed to novel ocular agent delivery systems and, in particular, emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.

Enhanced active agents

The teachings provide active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Methods of making and using the systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

Precision pharmaceutical 3D printing device

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

Method for preparing resveratrol compound

The present invention provides a method for preparing a resveratrol compound, and belongs to the technical field of organic synthesis. In the present invention, first alkoxy-substituted benzyl halide, alkoxy-substituted benzaldehyde and a metal catalyst are subjected to oxidative addition and reduction elimination reactions to obtain alkoxy-substituted diphenylethanone; and then the alkoxy-substituted diphenylethanone and a metal catalyst are subjected to reduction, trans elimination and selective debenzylation reactions under a hydrogen atmosphere to obtain the resveratrol compound. In the preparation method of the present invention, the hydrogenation reduction, trans elimination and selective debenzylation reactions can be achieved just by a one-pot process, where the reaction directly obtains a trans olefin, thereby avoiding the formation of a isomer; and also the reaction selectively catalyzes debenzylation to eliminate Lewis acids from the source, and has the advantage of a high yield ...

Controlled release dosage form

The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

Backlight module

Disclosed is a backlight module. The backlight module includes a backplane. The backplane is provided with a groove therethrough. Two sides and/or two ends of an optical diaphragm of the backlight module each are connected with a bendable flap which passes through the groove and is attached to the backplane. The backlight module has a simple structure without a plastic frame or a frame sealant, and an optical diaphragm in the backlight module can be fixed. A super narrow frame of the backlight module can be realized.

High-throughput and high-precision pharmaceutical additive manufacturing system

The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of ...

POROUS LAYERED TRANSITION METAL DICHALCOGENIDE AND PREPARATION METHOD AND USE THEREOF

The present invention relates to the field of catalysts, and provides a porous layered transition metal dichalcogenide (TMD) and a preparation method and use thereof. The preparation method includes the following steps: (1) mixing silica microspheres, a transition metal salt and an elemental chalcogen, and pressing to obtain a tablet, the silica microspheres having a same or different particle diameters; and (2) sintering the tablet under hydrogen, and removing the silica microspheres to obtain the porous layered TMD. The porous layered TMD prepared by the method of the present invention has a high lattice edge exposure, which provides more active sites and higher catalytic activity, so the porous layered TMD can effectively catalyze the oxidation of alcohols to aldehydes or sulfides to sulfoxides under visible light irradiation.

Shoe sole

PLASTIC FRAME FOR BACKLIGHT MODULE AND BACKLIGHT MODULE, AND LIQUID CRYSTAL DISPLAY MODULE

The present disclosure provides a plastic frame for a backlight module. The plastic frame includes a glass cover plate, and edge bars including a first edge bar provided with an LED placing groove for insertion of lamp beads of the light bars and a second edge bar, that are provided at two opposite sides of the glass cover plate close to an edge, respectively, wherein the LED placing groove passes through one side of the first edge bar being opposite to the second edge bar and one side of the first edge bar deviating away from the second edge bar. The present disclosure also provides a backlight module and a liquid crystal display module.

Oral drug dosage form comprising drug in the form of nanoparticles

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Identity authentication by using human biological characteristic

A human biological characteristic file corresponding to a particular identity is received and used as a base file. A characteristic code to be authenticated is obtained according to a human biological characteristic of a person who requests identity authentication when an identity authentication request corresponding to the particular identity is received. A base characteristic code is collected from a base file. A collecting algorithm applied for collecting the base characteristic code is the same as or matches an algorithm applied for obtaining the characteristic code. The present techniques determine whether the base characteristic code and the characteristic code correspond to a same human biological characteristic. If a result is positive, the identity authentication request is verified. The present techniques implement communication between different terminal devices of different manufacturers and effectively improve user experiences, thereby efficiently and conveniently implementing ...

System for optimizing switching dead-time and method of making same

A system for optimizing switching dead-time includes a power converter that includes a half-bridge circuit comprising a first switch coupled in series with a second switch, first and second state detection circuits respectively coupled to the first and second switches and configured to respectively detect an activation state of the first and second switches. First and second switch control circuits coupled respectively to the first and second switches are configured to respectively toggle the first and second switches between an activate state and a deactivated state. The first switch control circuit includes a first input configured to receive an activation signal from the second state detection circuit indicative of the activation state of the second switch, and the second switch control circuit includes a first input configured to receive an activation signal from the first state detection circuit indicative of the activation state of the first switch.

Oral drug dosage form comprising various release profiles

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Systems for stabilizing and delivering active agents

A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

METHOD AND SYSTEM FOR EXTRACTING CHARACTERISTIC INFORMATION

Extracting characteristic information includes receiving a collection command from a client, obtaining, via a collection device, biometric information based on the collection command, selecting a stored extraction algorithm corresponding to the client, the stored extraction algorithm being selected from among a plurality of stored extraction algorithms, extracting characteristic values from the obtained biometric information, the characteristic values being extracted based on the selected extraction algorithm, and sending the extracted characteristic values to the client. 1. A system , comprising:a receiving module configured to receive a collection command from a client;an information obtaining module configured to obtain, via a collection device, biometric information based on the collection command;a function extracting module configured to select an extraction algorithm corresponding to the client, the selected extraction algorithm being selected from among a plurality of stored extraction algorithms;a characteristic value extracting module configured to extract characteristic values from the biometric information, the characteristic values being extracted based on the selected extraction algorithm; anda sending module configured to send the extracted characteristic values to the client.2. The system as described in claim 1 , wherein the information obtaining module is further configured to:send the collection command to the collection device; andreceive the biometric information collected by the collection device after the receiving module performs collection.3. The system as described in claim 1 , wherein the function extracting module is further configured to determine the extraction algorithm corresponding to identifying information of the client claim 1 , the identifying information of the client being included in the collection command.4. The system as described in claim 1 , wherein:a storage module is configured to acquire the extraction algorithm ...

Synthetic antibody mimic peptides

The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins.

DRIVE SYSTEM WITH COMMON DC BUS

A system includes: a pre-charge circuit configured to produce direct current (DC) electrical power; a common DC bus; and a plurality of inverters, each inverter including: a local DC bus; a capacitor network connected to the local DC bus; an electrical network connected to the local DC bus, the electrical network configured to generate an alternating current (AC) drive signal; and a plurality of switching assemblies, each switching assembly being associated with one of the inverters, and each switching assembly configured to control whether the local DC bus and the capacitor network of the associated inverter are electrically connected to the common DC bus or to the pre-charge circuit. 1. A system comprising:a pre-charge circuit configured to produce direct current (DC) electrical power;a common DC bus; and a local DC bus;', 'a capacitor network connected to the local DC bus;', 'an electrical network connected to the local DC bus, the electrical network configured to generate an alternating current (AC) drive signal; and, 'a plurality of inverters, each inverter comprisinga plurality of switching assemblies, each switching assembly being associated with one of the inverters, and each switching assembly configured to control whether the local DC bus and the capacitor network of the associated inverter are electrically connected to the common DC bus or to the pre-charge circuit.2. The system of claim 1 , wherein the pre-charge circuit is configured to provide DC electrical power to the capacitor network of the local DC bus of at least one of the plurality of inverters while the local DC bus of at least one other of the plurality of inverters is electrically connected to the common DC bus.3. The system of claim 1 , wherein the pre-charge circuit is electrically connected to an AC electrical power source and further comprises at least one electronic element configured to convert AC electrical power to DC electrical power.4. The system of claim 3 , wherein the at least ...

Delivering enhanced active agents

The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

SYSTEM FOR OPTIMIZING SWITCHING DEAD-TIME AND METHOD OF MAKING SAME

A system for optimizing switching dead-time includes a power converter that includes a half-bridge circuit comprising a first switch coupled in series with a second switch, first and second state detection circuits respectively coupled to the first and second switches and configured to respectively detect an activation state of the first and second switches. First and second switch control circuits coupled respectively to the first and second switches are configured to respectively toggle the first and second switches between an activate state and a deactivated state. The first switch control circuit includes a first input configured to receive an activation signal from the second state detection circuit indicative of the activation state of the second switch, and the second switch control circuit includes a first input configured to receive an activation signal from the first state detection circuit indicative of the activation state of the first switch. 1. A power converter comprising:a half-bridge circuit comprising a first switch coupled in series with a second switch;a first state detection circuit coupled to the first switch and configured to detect an activation state of the first switch;a second state detection circuit coupled to the second switch and configured to detect an activation state of the second switch;a first switch control circuit coupled to the first switch and configured to toggle the first switch between an activate state and a deactivated state, the first switch control circuit comprising a first input configured to receive an activation signal from the second state detection circuit indicative of the activation state of the second switch;a second switch control circuit coupled to the second switch and configured to toggle the second switch between an active state and a deactivated state, the second switch control circuit comprising a first input configured to receive an activation signal from the first state detection circuit indicative of ...

Precision pharmaceutical 3D printing device

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

IDENTITY AUTHENTICATION BY USING HUMAN BIOLOGICAL CHARACTERISTIC

A human biological characteristic file corresponding to a particular identity is received and used as a base file. A characteristic code to be authenticated is obtained according to a human biological characteristic of a person who requests identity authentication when an identity authentication request corresponding to the particular identity is received. A base characteristic code is collected from a base file. A collecting algorithm applied for collecting the base characteristic code is the same as or matches an algorithm applied for obtaining the characteristic code. The present techniques determine whether the base characteristic code and the characteristic code correspond to a same human biological characteristic. If a result is positive, the identity authentication request is verified. The present techniques implement communication between different terminal devices of different manufacturers and effectively improve user experiences, thereby efficiently and conveniently implementing remote identity authentication. 1. A method comprising:receiving a human biological characteristic file of a particular identity as a base file;receiving a request for an identity authentication corresponding to the particular identity;obtaining a first characteristic code corresponding to a human biological characteristic of a person who requests the identity authentication;collecting a second characteristic code from the base file by using a collecting algorithm for collecting the second characteristic code that matches a collecting algorithm for collecting the first characteristic code;determining whether the second characteristic code and the first characteristic code correspond to a same human biological characteristic; andverifying the request for the identity authentication in response to determining that the second characteristic code and the first characteristic code correspond to the same human biological characteristic.2. The method of claim 1 , wherein the obtaining ...

Oral drug dosage forms having desired drug release profiles and uses thereof

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Plastic frame for backlight module and backlight module, and liquid crystal display module

The present disclosure provides a plastic frame for a backlight module. The plastic frame includes a glass cover plate, and edge bars including a first edge bar provided with an LED placing groove for insertion of lamp beads of the light bars and a second edge bar, that are provided at two opposite sides of the glass cover plate close to an edge, respectively, wherein the LED placing groove passes through one side of the first edge bar being opposite to the second edge bar and one side of the first edge bar deviating away from the second edge bar. The present disclosure also provides a backlight module and a liquid crystal display module.

Core-shell structure supported tungsten composite catalyst and preparation method and use thereof

The present invention discloses a core-shell structure supported tungsten composite catalyst and a preparation method and use thereof. Most of the existing synthesis methods of the main ring of quinolone drugs have the defects of many synthesis steps, cumbersome operation, large amount of three wastes, higher costs and the like. The present invention prepares a magnetic separable core-shell supported tungsten composite catalyst, WO3/SiO2/Fe3O4, by preparing Fe3O4 colloid and SiO2/Fe3O4 composite nano-particles. This magnetic separable core-shell supported tungsten composite catalyst, WO3/SiO2/Fe3O4, is used to catalyze and synthesize quinolone compounds. The present invention provides an efficient preparation method of quinolone compounds using a catalyst which can be recovered by magnetic separation and recycled. The catalyst prepared by the present invention can be reused in the preparation of quinolone compounds and still retains the original activity without deactivation, which not ...

Backlight assembly and liquid crystal display assembly

The present invention provides a backlight assembly which includes a plastic frame, the plastic frame, a light guide plate, a light bar and an optical diaphragm group, a side surface of the plastic frame deviating from the reflective sheet is provided with a double-sided adhesive, at least one side frame of the plastic frame is provided with a groove which is disposed at a side surface of the plastic frame opposite to the double-sided adhesive; the double-sided adhesive includes a conductive heat dissipation layer and a double-sided adhesive layer, and a first metal sheet is disposed on a double-sided adhesive layer, located on the groove and contacts the optical diaphragm group and the conductive heat dissipation layer, respectively. The present invention further provides a liquid crystal display assembly.

VARIABLE FREQUENCY DRIVE CIRCUIT WITH OVERVOLTAGE PROTECTION

A variable frequency drive (VFD) circuit includes an input connectable to an AC source, a rectifier to convert an AC power input to a DC power, a DC link to receive DC power from the rectifier and having a DC link voltage thereon, a DC link capacitor bank with one or more capacitors connected to the DC link, and a pre-charge circuit coupled to the DC link capacitor. The pre-charge circuit further includes one or more resistors, one or more pre-charge relays each operable in on and off states to selectively control a current flow through the resistor(s) so as to control an initial pre-charge of the DC link capacitor, and an overvoltage relay operable in on and off states to selectively cut-off a current flow to the DC link capacitor bank, so as to prevent an overvoltage condition in the DC link capacitor bank. 1. A variable frequency drive (VFD) circuit comprising:an input connectable to an AC source;a rectifier connected to the input to convert an AC power input to a DC power;a DC link coupled to the rectifier to receive the DC power therefrom, the DC link having a DC link voltage thereon;a DC link capacitor bank comprising one or more capacitors connected to the DC link to smooth the DC link voltage; and one or more resistors;', 'one or more pre-charge relays each operable in an on and off state to selectively control a current flow through the one or more resistors, so as to control an initial pre-charge of the DC link capacitor; and', 'an overvoltage relay operable in an on and off state to selectively cut-off a current flow to the DC link capacitor bank, so as to prevent an overvoltage condition in the DC link capacitor bank., 'a pre-charge circuit coupled to the DC link capacitor bank, the pre-charge circuit comprising2. The VFD circuit of further comprising:one or more voltage sensors to measure the DC link voltage; anda controller that receives an input from the one or more voltage sensors regarding the measured DC link voltage, the controller being ...

MULTI-CHAMBER TIRE MANUFACTURING MOLD

A multi-chamber tire manufacturing mold, comprising an upper holding plate and a lower holding plate having an interval between the upper holding plate and the lower holding plate; a tire periphery forming slider, a tire inner chamber forming slider, an upper mold block, a lower mold block, and a central mold post are arranged in the interval; the upper holding plate is connected to the plurality of upper mold blocks, and the lower holding plate is connected to a plurality of lower mold blocks, forming an enclosed chamber; the tire inner chamber forming slider arranged in the enclosed chamber, forming a flexible portion chamber and a partitioned chamber, such that isolating chambers are formed in the flexible portion; the openings of which together with the tire periphery forming slider form an enclosed chamber via process sealing members and fill the forming outer body. 1. A multi-chamber tire manufacturing mold , wherein the multi-chamber tire manufacturing mold comprises an upper holding plate and a lower holding plate; the upper holding plate and the lower holding plate are arranged alternately and in parallel with each other with intervals between the upper holding plate and the lower holding plate;a plurality of tire periphery forming sliders, upper mold blocks, lower mold blocks and central mold posts are arranged in the intervals; the tire periphery forming sliders are arranged along the height direction of the intervals, and the plurality of tire periphery forming sliders are connected in order and arranged in an annular fashion; the central mold posts are arranged along the height direction of the intervals in an annular fashion, and located at an inner side of the plurality of tire periphery forming sliders, and arranged alternately with the plurality of tire periphery forming sliders; the central mold post is configured inside with a forming part which is arranged around the central mold post;a lower end of the upper holding plate is connected with a ...

Electric vehicle chassis and electric vehicle using same

Disclosed are an electric vehicle chassis and an electric vehicle using the electric vehicle chassis. The electric vehicle chassis comprises a frame system (2), a steering motor damping system (13), a wheel system (12), a steering system (3) and a braking system (14), wherein the wheel system (12) comprises a left front wheel (121) using a hub motor, a left rear wheel (123) using a hub motor, a right front wheel (122) using a hub motor, and a right rear wheel (124) using a hub motor; and the steering motor damping system (13) comprises a left front steering damping motor (131), a right front steering damping motor (133), a left rear steering damping motor (135) and a right rear steering damping motor (137). Driving the wheels with the hub motors can omit a traditional mechanical transmission system, so as to simplify the structure of the chassis, reduce the weight of the chassis, and also reduce the mechanical transmission loss, thereby improving the power utilization efficiency.

SYSTEM AND METHOD FOR CAPACITOR FAULT ENERGY INTERRUPTION IN ADJUSTABLE SPEED DRIVES

An adjustable speed drive (ASD) circuit includes a rectifier bridge to convert an AC power input to a DC power, a DC link coupled to the rectifier bridge to receive the DC power, a DC link capacitor bank comprising at least first and second capacitors connected to the DC link, each capacitor having a capacitor voltage thereacross, and a protection circuit including a detection circuit configured to detect a short circuit on one or more of the first and second capacitors of the DC link capacitor bank and generate an action signal upon detection of a short circuit on one or more of the first and second capacitors of the DC link capacitor bank. The ASD circuit also includes an action circuit in operable communication with the detection circuit and configured to cause a short circuit across the DC link upon receiving the action signal from the detection circuit. 1. An adjustable speed drive (ASD) circuit comprising:an input connectable to an AC source;a rectifier bridge connected to the input to convert an AC power input to a DC power;a DC link coupled to the rectifier bridge to receive the DC power therefrom;a DC link capacitor bank comprising at least first and second capacitors connected to the DC link, each capacitor of the DC link capacitor bank having a capacitor voltage thereacross; and [ detect a short circuit on one or more of the first and second capacitors of the DC link capacitor bank; and', 'generate an action signal upon detection of a short circuit on one or more of the first and second capacitors of the DC link capacitor bank; and, 'a detection circuit configured to, 'an action circuit in operable communication with the detection circuit and configured to cause a short circuit across the DC link upon receiving the action signal from the detection circuit., 'a protection circuit comprising2. The ASD circuit of wherein the detection circuit comprises:a first opto-coupler operably connected to the first capacitor; anda second opto-coupler operably connected ...

System and method for intelligent circuit breaking in adjustable speed drives

An ASD circuit includes an input, solid-state switch rectifier bridge, DC link, and DC link capacitor bank. A pre-charge circuit is coupled between the input and the DC link capacitor bank and includes pre-charge relays operable in an on state that allows the AC power input to power the rectifier bridge during a normal operating state and an off state that allows the AC power input to pre-charge the DC link capacitor bank through a pre-charge resistor of the pre-charge circuit during a pre-charge operating state. A protection relay of a protection circuit is coupled between the pre-charge relays and the DC link capacitor bank, the protection relay operable in an on state that prevents the pre-charge circuit from connecting to the DC link capacitor bank when a capacitor short circuit occurs and an off state that allows the pre-charge circuit to electrically connect to the DC link capacitor bank.

Method and system for extracting characteristic information

Extracting characteristic information includes receiving a collection command from a client, obtaining, via a collection device, biometric information based on the collection command, selecting a stored extraction algorithm corresponding to the client, the stored extraction algorithm being selected from among a plurality of stored extraction algorithms, extracting characteristic values from the obtained biometric information, the characteristic values being extracted based on the selected extraction algorithm, and sending the extracted characteristic values to the client.

Precision pharmaceutical 3D printing device

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

System and method for single-phase and three-phase current determination in power converters and inverters

A system and method for capturing current information for a power converter is disclosed. The current monitoring system includes a control system operably connected to a circuit having a plurality of semiconductor switches that are controllable to convert an input power to an output power having a desired voltage and current. The control system includes a PWM signal generator to generate switching signals that control switching of the switches, gate drivers to facilitate switching of the switches, and desaturation circuits to provide overcurrent protection to the switches. The control system further includes a processor that receives voltage data from the desaturation circuits regarding a measured voltage across each of the switches, determines a current through each of the switches based on the voltage across each respective switch, and calculates an input current to the circuit or an output current of the circuit based on the determined currents through the switches.

IDENTITY AUTHENTICATION BY USING HUMAN BIOLOGICAL CHARACTERISTIC

A human biological characteristic file corresponding to a particular identity is received and used as a base file. A characteristic code to be authenticated is obtained according to a human biological characteristic of a person who requests identity authentication when an identity authentication request corresponding to the particular identity is received. A base characteristic code is collected from a base file. A collecting algorithm applied for collecting the base characteristic code is the same as or matches an algorithm applied for obtaining the characteristic code. The present techniques determine whether the base characteristic code and the characteristic code correspond to a same human biological characteristic. If a result is positive, the identity authentication request is verified. The present techniques implement communication between different terminal devices of different manufacturers and effectively improve user experiences, thereby efficiently and conveniently implementing remote identity authentication.

Salad maker

Oral drug dosage forms compromising a fixed-dose of an ADHD non-stimulant and an ADHD stimulant

The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.

DOSAGE FORMS AND USE THEREOF

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner. 1. A dosage form comprising:a substrate that forms a compartment; anda drug content loaded into the compartment.2. The dosage form of claim 1 , wherein the drug content is operably linked to the substrate.3. The dosage form of claim 1 , wherein the drug content is detached from the substrate.4. The dosage form of claim 1 , wherein the substrate is made from at least one thermoplastic material.5. The dosage form of claim 4 , wherein the thermoplastic material is selected from the group consisting of a hydrophilic polymer claim 4 , a hydrophobic polymer claim 4 , a swellable polymer claim 4 , a non-swellable polymer claim 4 , a porous polymer claim 4 , a non-porous polymer claim 4 , an erodible polymer claim 4 , a non-erodible polymer.6. The dosage form of claim 1 , wherein the compartment has a shape selected from the group consisting of a pie shape claim 1 , a cone shape claim 1 , a pyramid shape claim 1 , a cylindrical shape claim 1 , a cubic or cuboidal shape claim 1 , a triangular or polygonal prism shape claim 1 , a tetrahedron and a combination thereof.7. The dosage form of claim 1 , wherein the drug content comprises an active pharmaceutical ingredient (API).8. The dosage form of claim 7 , wherein the drug content further comprises a medium.9. The dosage form of claim 8 , wherein the medium is made from a thermoplastic material.10. The dosage form of claim 8 , wherein the medium has a higher erosion/dissolution rate than the API.11. The dosage form of claim 8 , wherein the medium has a higher erosion/dissolution rate than the substrate.12. The dosage form of claim 1 , wherein the compartment has an aperture which is ...

BACKLIGHT MODULE

Disclosed is a backlight module. The backlight module includes a backplane. The backplane is provided with a groove therethrough. Two sides and/or two ends of an optical diaphragm of the backlight module each are connected with a bendable flap which passes through the groove and is attached to the backplane. The backlight module has a simple structure without a plastic frame or a frame sealant, and an optical diaphragm in the backlight module can be fixed. A super narrow frame of the backlight module can be realized.

High-throughput and high-precision pharmaceutical additive manufacturing system

The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of ...

High-throughput and high-precision pharmaceutical additive manufacturing system

The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of ...

Enhanced anticancer agent

The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

Control and protection apparatus for electric motor

A control and protection apparatus for an electric motor, comprising an inverter (3), a first converter (1), a temperature detection apparatus (7), and a second converter (2). The first converter (1) is used for generating, on the basis of an input signal, a first control signal to control working of the inverter (3). The temperature detection apparatus (7) is used for detecting the temperature of the electric motor (4) and for acquiring a temperature signal. The second converter (2) is used for generating a second control signal on the basis of the temperature signal detected and for providing the second control signal to the inverter (3). The inverter (3) is used for controlling wording of the electric motor (4) on the basis of the first control signal and of the second control signal. The control and protection apparatus for the electric motor is low in costs and high in safety and reliability.

Enhanced SN-38 anticancer agent

The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e.g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e.g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e.g., a drug) or a reagent, and/or amount of the compound (e.g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Core-shell structure supported tungsten composite catalyst and preparation method and use thereof

The present invention discloses a core-shell structure supported tungsten composite catalyst and a preparation method and use thereof. Most of the existing synthesis methods of the main ring of quinolone drugs have the defects of many synthesis steps, cumbersome operation, large amount of three wastes, higher costs and the like. The present invention prepares a magnetic separable core-shell supported tungsten composite catalyst, WO3/SiO2/Fe3O4, by preparing Fe3O4 colloid and SiO2/Fe3O4 composite nano-particles. This magnetic separable core-shell supported tungsten composite catalyst, WO3/SiO2/Fe3O4, is used to catalyze and synthesize quinolone compounds. The present invention provides an efficient preparation method of quinolone compounds using a catalyst which can be recovered by magnetic separation and recycled. The catalyst prepared by the present invention can be reused in the preparation of quinolone compounds and still retains the original activity without deactivation, which not only greatly improves the production efficiency, but also reduces the environmental pollution.

SYSTEMS FOR STABILIZING AND DELIVERING ACTIVE AGENTS

A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. 121-. (canceled)25. A method of increasing the in vivo half-life of an active agent claim 23 , the method comprising covalently attaching the delivery system of to an active agent claim 23 , the active agent comprising a structure selected from the group consisting of a peptide claim 23 , an oligopeptide claim 23 , a polypeptide claim 23 , a protein claim 23 , an antibody claim 23 , an oligonucleotide claim 23 , a polynucleotide claim 23 , a virus-like particle claim 23 , a small molecule claim 23 , an oligosaccharide claim 23 , an imaging agent claim 23 , and combinations thereof.26. A method of increasing the in vivo half-life of an active agent claim 24 , the method comprising covalently attaching the delivery system of to an active agent claim 24 , the active agent comprising a structure selected from the group consisting of a peptide claim 24 , an oligopeptide claim 24 , a polypeptide claim 24 , a protein claim 24 , an antibody claim 24 , an oligonucleotide claim 24 , a polynucleotide claim 24 , a virus-like particle claim 24 , a small molecule claim 24 , an oligosaccharide claim 24 , an imaging agent claim 24 , and combinations thereof.27. A method of increasing the in vivo half-life of an active agent in blood serum claim 22 , the method comprising covalently attaching the delivery system of to an active agent claim 22 , the active agent comprising a structure selected from the group consisting of a peptide claim 22 , an oligopeptide claim 22 , a polypeptide claim 22 , a protein claim 22 , an antibody claim 22 , an oligonucleotide claim 22 , a polynucleotide claim 22 , a virus-like particle ...

CONJUGATION OF PHARMACEUTICALLY ACTIVE AGENTS WITH TRANSTHYRETIN LIGANDS THROUGH ADJUSTABLE LINKERS TO INCREASE SERUM HALF-LIFE

A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. 1. A delivery system for an active agent , comprising:{'sup': '−6', 'a ligand with (i) a high selectivity for a plasma protein endogeneous to the subject, the molecular weight of the plasma protein ranging from about 30 kDa to about 80 kDa; (ii) a high binding affinity, Kd, of at least 10M for the plasma protein; and, (iii) a molecular weight ranging from about 200 Da to about 2000 Da;'}and,a linker that ranges in length from about 10 angstroms to about 50 angstroms, or from 8 atoms to 50 atoms;wherein, the active agent has a structure selected from the group consisting of a peptide, an oligopeptide, a polypeptide, a protein, an antibody, an oligonucleotide, a polynucleotide, a virus-like particle, a small molecule, an imaging agent, and combinations thereof.2. (canceled)3. (canceled)4. The delivery system of claim 1 , wherein the plasma protein is TTR.8. (canceled)10. The delivery system of claim 9 , wherein:R1 is methyl and R3 is methyl;Xa is O, and,Y is fluoro or carboxyl.12. The delivery system of claim 11 , wherein Ris selected from bromo claim 11 , chloro and fluoro.20. A method of increasing the in vivo half-life of an active agent claim 5 , the method comprising covalently attaching the delivery system of to an active agent claim 5 , the active agent comprising a structure selected from the group consisting of a peptide claim 5 , an oligopeptide claim 5 , a polypeptide claim 5 , a protein claim 5 , an antibody claim 5 , an oligonucleotide claim 5 , a polynucleotide claim 5 , a virus-like particle claim 5 , a small molecule claim 5 , an oligosaccharide claim 5 , an imaging agent claim 5 , and ...

ORAL DRUG DOSAGE FORMS COMPROMISING A FIXED-DOSE OF AN ADHD NON-STIMULANT AND AN ADHD STIMULANT

The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein. 1. An oral drug dosage form comprising:(a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and', 'wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a sustained release profile and the ADHD stimulant is released according to an immediate release profile., '(b) an erodible stimulant material admixed with an ADHD stimulant,'}2. The oral drug dosage form of claim 1 , wherein the oral drug dosage form comprises a multi-layered structure comprising a plurality of layers of the erodible non-stimulant material admixed with the ADHD non-stimulant.34-. (canceled)5. The oral drug dosage form of claim 2 , wherein each layer of the erodible non-stimulant material admixed with the ADHD non-stimulant of the multi-layered structure has a pre-determined surface area claim 2 , thickness claim 2 , and ADHD non-stimulant mass ...

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or areagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

ENHANCED ACTIVE AGENTS

The teachings provide active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Methods of making and using the systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. 4. The enhanced active agent of claim 1 , the drug having a structure selected from the group consisting of a peptide claim 1 , an oligopeptide claim 1 , a polypeptide claim 1 , a protein claim 1 , an antibody claim 1 , an oligonucleotide claim 1 , a polynucleotide claim 1 , a virus-like particle claim 1 , a small molecule claim 1 , an oligosaccharide claim 1 , an imaging agent claim 1 , and combinations thereof.5. The enhanced active agent of claim 1 , the drug having an increased half-life in blood serum when conjugated to the delivery system.6. The enhanced active agent of claim 1 , the drug having a reduced immunogenicity in blood serum when conjugated to the delivery system.7. The enhanced active agent of claim 2 , the drug having an increased half-life in blood serum when conjugated to the delivery system.8. The enhanced active agent of claim 2 , the drug having a reduced immunogenicity in blood serum when conjugated to the delivery system.9. The enhanced active agent of claim 3 , the drug having an increased half-life in blood serum when conjugated to the delivery system.10. The enhanced active agent of claim 3 , the drug having a reduced immunogenicity in blood serum when conjugated to the delivery system.11. The enhanced active agent of claim 4 , the drug having an increased half-life in blood serum when conjugated to the delivery system.12. The enhanced active agent of claim 4 , the drug having a reduced immunogenicity in blood serum when conjugated to the delivery system ...

LIGHT-TRANSMITTING DISPLAY PANEL, DISPLAY PANEL AND DISPLAY APPARATUS

A light-transmitting display panel, display panel and display apparatus. The light-transmitting display panel includes a first pixel array including a first minimum repeating unit. The first minimum repeating unit includes at least one light-transmitting column unit. The at least one light-transmitting column unit has a central axis parallel to an extending direction of the at least one light-transmitting column unit. The at least one light-transmitting column unit includes a plurality of first sub-pixels spaced apart from one another in the extending direction of the at least one light-transmitting column unit. At least one of the first sub-pixels in the at least one light-transmitting column unit is set to deviate from the central axis. 1. A light-transmitting display panel , comprising:a first pixel array comprising a first minimum repeating unit, the first minimum repeating unit comprising at least one light-transmitting column unit, the at least one light-transmitting column unit having a central axis parallel to an extending direction of the at least one light-transmitting column unit and comprising a plurality of first sub-pixels spaced apart from one another in the extending direction of the at least one light-transmitting column unit,wherein at least one of the first sub-pixels in the at least one light-transmitting column unit is set to deviate from the central axis.2. The light-transmitting display panel of claim 1 , wherein the plurality of first sub-pixels in the at least one light-transmitting column unit are arranged in a curved arrangement structure.3. The light-transmitting display panel of claim 1 , wherein the plurality of first sub-pixels in the at least one light-transmitting column units are arranged in an arcuate arrangement structure.4. The light-transmitting display panel of claim 1 , wherein in the first minimum repeating unit claim 1 , the at least one light-transmitting column unit comprises at least two light-transmitting column units ...

SYNTHETIC ANTIBODY MIMIC PEPTIDES

The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins. 1. An isolated antibody mimic peptide comprising at least one of a motif sequence SEQ ID NO:78 or the reverse of said motif sequence , said motif sequence having Namino acids , wherein P is proline , W is tryptophan , E is glutamic acid , F is phenylalanine , Y is tyrosine , A is alanine , and each of X , X , X , Xand Xis any of 0 to 8 amino acids; and , wherein P is at amino acid position N/2 of the motif sequence or next thereto.2. The peptide of claim 1 , wherein the FY in the motif sequence is replaced with YW claim 1 , YL claim 1 , YI claim 1 , YV claim 1 , YF claim 1 , WY claim 1 , LY claim 1 , IY claim 1 , VY claim 1 , YY claim 1 , TYY claim 1 , TYW claim 1 , TYL claim 1 , TYI claim 1 , TYV claim 1 , TYF claim 1 , TWY claim 1 , TLY claim 1 , TIY claim 1 , TVY claim 1 , or TFY claim 1 , wherein L is leucine claim 1 , I is isoleucine claim 1 , and V is valine.3. The motif sequence of wherein the length of the sequence ranges from 7 to 25 amino acids.4. The motif sequence of wherein the sequence comprises 7 claim 2 , 10 claim 2 , 15 claim 2 , 20 claim 2 , or 25 amino acids.5. The peptide of claim 1 , wherein the peptide is conjugated to a substance.6. The peptide of claims 5 , wherein the substance is a therapeutic or a detective: agent.7. Method for diagnosing a disease comprising a ...

SYSTEM AND METHOD FOR ADDITIVELY MANUFACTURING BOILER TUBES

A method of manufacturing a tube is provided. The method includes: selecting a core pipe having a thickness that is initially less than a desired thickness of the tube; and building-up an outer layer over an exterior surface of the core pipe via additive manufacturing so as to increase the thickness of the core pipe such that the thickness of the core pipe is equal to the desired thickness of the tube. 1. A method of manufacturing a tube comprising:selecting a core pipe having a thickness that is initially less than a desired thickness of the tube; andbuilding-up an outer layer over an exterior surface of the core pipe via additive manufacturing so as to increase the thickness of the core pipe such that the thickness of the core pipe is equal to the desired thickness of the tube.2. The method of claim 1 , wherein building-up an outer layer over an exterior surface of the core pipe via additive manufacturing comprises:weld strip cladding the outer layer onto the exterior surface of the core pipe.3. The method of claim 1 , wherein the core pipe comprises a first material and the outer layer comprises a second material different from the first material.4. The method of further comprising:building fittings into the outer layer via additive manufacturing.5. The method of claim 4 , wherein the fittings include at least one of a nipple claim 4 , a nozzle claim 4 , a tee claim 4 , a weld-o-let claim 4 , an elbow claim 4 , and a reducer.6. The method of wherein the fitting defines a flow path and the method further comprises:boring through the outer layer and the core pipe such that the flow path is fluidly connected to an interior cavity of the core pipe.7. The method of further comprising:cutting the core pipe such that a length of the core pipe is equal to a desired length of the tube.8. The method of further comprising:extending a length of the core pipe via connecting the core pipe to another core pipe such that a combined length of the connected core pipes is equal to ...

CONTROLLED RELEASE DOSAGE FORM

The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content. 1. A solid pharmaceutical dosage form comprising:a substrate that forms a compartment, wherein the substrate comprises at least a first piece and a second piece, wherein the first piece operably links to the second piece;a drug content loaded into the compartment; anda releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating said first and second piece to release the drug content.2. The dosage form of claim 1 , wherein the compartment has an aperture which is sealed by the releaser.3. The dosage form of claim 1 , wherein the releaser comprises a hydrogel.4. The dosage form of claim 1 , wherein the releaser comprises an effervescent material loaded in the compartment.5. The dosage form of claim 4 , wherein the effervescent material is selected from the group consisting of sodium carbonate claim 4 , sodium bicarbonate claim 4 , sodium metabisulphite claim 4 , calcium carbonate and combinations thereof.6. The dosage form of claim 1 , wherein the substrate is made from a thermoformable material.7. The dosage form of claim 4 , wherein the thermoformable material is selected from the group consisting of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer 57/30/13 claim 4 , polyvinylpyrrolidone ...

3D PRINTING DEVICE AND METHOD

A 3D printing device (), comprising a melt extrusion module (), a printing module (), and a platform module (). The melt extrusion module () comprises a processing chamber () consisting of a feed inlet () and a discharge outlet (), as well as an extrusion means () and a heating means () disposed at the processing chamber; the melt extrusion module () is configured to receive an initial material from the feed inlet () of the processing chamber (), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet () of the processing chamber (). The printing module () is communicated with the discharge outlet () of the processing chamber () and is provided with a nozzle (); the printing module () is configured to receive the molten body extruded from the discharge outlet () of the processing chamber () and guide the molten body to be extruded out of the nozzle (). The platform module () is configured to receive the molten body extruded from the nozzle (). 176-. (canceled)77. A 3D printing method of making a pharmaceutical dosage form , comprising:feeding a first initial pharmaceutical material to a processing chamber of a first melt extrusion module;heating and extruding the first initial pharmaceutical material in the processing chamber of the first melt extrusion module, so that the first initial pharmaceutical material is converted into a first melt and the first melt is extruded from a discharge outlet of the processing chamber of the first melt extrusion module; andguiding the first melt at the discharge outlet of the processing chamber of the first melt extrusion module to be extruded through a first nozzle of a first printing module and deposited on a platform module.78. The 3D printing method of claim 77 , further comprising:feeding the first initial pharmaceutical material to the first melt extrusion module through a hopper of a first feeding module; andcontrolling the discharge speed ...

HIGH-THROUGHPUT AND HIGH-PRECISION PHARMACEUTICAL ADDITIVE MANUFACTURING SYSTEM

The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of the pharmaceutical product. 1. A system for creating pharmaceutical products by additive manufacturing , comprising:a material supply module for receiving a set of printing materials; wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate;', 'wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows;, 'a flow distribution module comprising a flow distribution plate,'}a plurality of nozzles; andone or more controllers for controlling the plurality of nozzles to dispense the plurality of flows based on a plurality of nozzle-specific parameters.2. The system of claim 1 , further comprising a printing platform configured to receive the dispensed plurality of flows claim 1 , wherein the printing platform is configured to move to form a batch of the pharmaceutical product.3. (canceled)4. The system of claim 1 , wherein the ...

ELECTRIC VEHICLE CHASSIS AND ELECTRIC VEHICLE USING SAME

Disclosed are an electric vehicle chassis and an electric vehicle using the electric vehicle chassis. The electric vehicle chassis comprises a frame system (), a steering motor damping system (), a wheel system (), a steering system () and a braking system (), wherein the wheel system () comprises a left front wheel () using a hub motor, a left rear wheel () using a hub motor, a right front wheel () using a hub motor, and a right rear wheel () using a hub motor; and the steering motor damping system () comprises a left front steering damping motor (), a right front steering damping motor (), a left rear steering damping motor () and a right rear steering damping motor (). Driving the wheels with the hub motors can omit a traditional mechanical transmission system, so as to simplify the structure of the chassis, reduce the weight of the chassis, and also reduce the mechanical transmission loss, thereby improving the power utilization efficiency. 1. An electric vehicle chassis comprising a frame system , a steering motor damping system mounted on the frame system , a wheel system connected with the steering motor damping system , a steering system mounted on the frame system and a braking system mounted on the frame system , wherein the wheel system comprises a left front wheel using a hub motor , a left rear wheel using a hub motor , a right front wheel using a hub motor , and a right rear wheel using a hub motor; and the steering motor damping system comprises a left front steering damping motor , a right front steering damping motor , a left rear steering damping motor and a right rear steering damping motor; the left front steering damping motor and the right front steering damping motor are respectively disposed on a left side and a right side of a front end of the frame system , the left rear steering damping motor and the right rear steering damping motor are respectively disposed on the left side and the right side of a rear end of the frame system; the left ...

ORAL DRUG DOSAGE FORMS HAVING A DESIRED PK PROFILE AND METHODS OF DESIGNING AND PRODUCING THEREOF

The present disclosure, in some aspects, is directed to methods of designing an oral drug dosage form formulated and configured to have a desired pharmacokinetic profile. In other aspects, the present disclosure is directed to oral drug dosage forms having a desired pharmacokinetic profile, and methods of making, such as three-dimensional printing, such oral drug dosage forms. 171-. (canceled)73: The method of claim 72 , wherein the individual is a human.74: The method of claim 72 , wherein the drug has linear pharmacokinetics.75: The method of claim 72 , wherein the MR1 portion is a MR1 layer.76: The method of claim 72 , wherein the MR2 portion is a MR2 layer.77: The method of claim 72 , wherein the MR1 portion is an immediate-release (IR) portion having an immediate-release profile claim 72 , and wherein the MR2 portion is an extended-release (ER) portion having an extended-release profile.78: The method of claim 72 , wherein the MR1 portion is a first extended-release (ER) portion having an extended-release profile claim 72 , and wherein the MR2 portion is a second extended-release (ER) portion having an extended-release profile.79: The method of claim 72 , wherein the MR1 portion is a first immediate-release (IR) portion having an immediate-release profile claim 72 , and wherein the MR2 portion is a second immediate-release (IR) portion having an immediate release profile.80: The method of claim 77 , wherein the MR1 portion and the MR2 portion are stacked on top of each other.81: The method of claim 80 , wherein the MR1 portion and MR2 portion are partially surrounded by a shell claim 80 , and wherein the shell has a slower dissolution rate than the ER portion.82: The method of claim 81 , wherein the shell comprises an enteric material.83: The method of claim 80 , wherein the MR1 portion has a top surface and a bottom surface claim 80 , wherein the MR2 portion has a top surface and a bottom surface claim 80 , and wherein the shell is in direct contact with both ...

ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner. 1. A tablet comprising a plurality of layers , wherein each layer comprises a substrate , and wherein the table comprises a drug in the form of nanoparticles disposed between at least two of the plurality of layers.2. The tablet of claim 1 , comprising a first layer claim 1 , a second layer claim 1 , a third layer claim 1 , a first drug in the form of nanoparticles disposed between the first layer and the second layer claim 1 , and a second drug in the form of nanoparticles disposed between the second layer and the third layer.3. The tablet of claim 2 , wherein the first drug and the second drug are different.4. The tablet of claim 2 , wherein the first drug and the second drug are the same.5. The tablet of claim 1 , wherein the substrate is erodible.6. The table of claim 1 , wherein the substrate thickness is different among each layer.7. The tablet of claim 1 , wherein the substrate thickness is the same among each layer.8. The tablet of claim 1 , wherein the substrate comprises a drug embedded therein.9. The tablet of claim 8 , wherein the drug embedded within the substrate of each layer is different.10. The tablet of claim 8 , wherein the drug embedded within the substrate of each layer is the same.11. The tablet of claim 1 , wherein the size of the nanoparticles is from about 1 nm to about 900 nm.12. The tablet of claim 1 , wherein the size of the nanoparticles is from about 100 nm to about 500 nm.13. The tablet of claim 1 , wherein the size of the nanoparticles is from about 100 nm to about 200 nm.1421-. (canceled)22. The tablet of claim 2 , wherein the substrate of each layer is erodible.23. The tablet of claim 2 , ...

ENHANCED ANTICANCER AGENT

The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. 4. The enhanced anticancer agent of claim 1 , the agent having an increased half-life in blood serum when conjugated to the delivery system.5. The enhanced anticancer agent of claim 1 , the agent having a reduced immunogenicity in blood serum when conjugated to the delivery system.6. The enhanced anticancer agent of claim 2 , the agent having an increased half-life in blood serum when conjugated to the delivery system.7. The enhanced anticancer agent of claim 2 , the agent having a reduced immunogenicity in blood serum when conjugated to the delivery system.8. The enhanced anticancer agent of claim 3 , the agent having an increased half-life in blood serum when conjugated to the delivery system.9. The enhanced anticancer agent of claim 3 , the agent having a reduced immunogenicity in blood serum when conjugated to the delivery system.10. The enhanced anticancer agent of claim 1 , wherein the linker claim 1 , R claim 1 , attaches (i) to the ligand through an ether bond and (ii) to the active agent through an amide bond.11. The enhanced anticancer agent of claim 1 , wherein the linker claim 1 , R claim 1 , attaches (i) to the ligand through an ether bond and (ii) to the active agent through an ester bond.12. A method of administering an enhanced anticancer agent to a subject claim 1 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'obtaining the enhanced anticancer agent of ; and,'}administering the ...

ORAL DRUG DOSAGE FORM COMPRISING DRUG IN THE FORM OF NANOPARTICLES

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner. 1. An oral drug dosage form comprising a plurality of layers , wherein each layer comprises a substrate , and wherein the oral drug dosage form comprises a drug in the form of nanoparticles disposed between at least two of the plurality of layers.2. The oral drug dosage form of claim 1 , comprising a first layer claim 1 , a second layer claim 1 , a third layer claim 1 , a first drug in the form of nanoparticles disposed between the first layer and the second layer claim 1 , and a second drug in the form of nanoparticles disposed between the second layer and the third layer.3. The oral drug dosage form of claim 2 , wherein the first drug and the second drug are different.4. The oral drug dosage form of claim 2 , wherein the first drug and the second drug are the same.5. The oral drug dosage form of claim 1 , wherein the substrate is erodible.6. The oral drug dosage form of claim 1 , wherein the substrate thickness is different among each layer.7. The oral drug dosage form of claim 1 , wherein the substrate thickness is the same among each layer.8. The oral drug dosage form of claim 1 , wherein the substrate comprises a drug embedded therein.9. The oral drug dosage form of claim 8 , wherein the drug embedded within the substrate of each layer is different.10. The oral drug dosage form of claim 8 , wherein the drug embedded within the substrate of each layer is the same.11. The oral drug dosage form of claim 1 , wherein the size of the nanoparticles is from about 1 nm to about 900 nm.12. The oral drug dosage form of claim 1 , wherein the size of the nanoparticles is from about 100 nm to about 500 nm.13. The oral drug dosage ...

Synthetic antibody mimic peptides

The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (PDCs) comprising the mimic peptides disclosed herein. The targets of these mimic peptides include epidermal growth factor receptor (EGFR), and human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). The present disclosure comprises application of the knob-socket computational model to design antibody mimics for proteins.

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e.g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e.g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e.g., a drug) or a reagent, and/or amount of the compound (e.g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

PRECISION PHARMACEUTICAL 3D PRINTING DEVICE

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position. 129-. (canceled)30. A method of manufacturing a pharmaceutical dosage form by additive manufacturing , comprising:melting and pressurizing a pharmaceutically acceptable material;monitoring a pressure of the material within a nozzle or within a feed channel proximal to the nozzle, wherein the nozzle comprises a tapered inner surface adjacent to an extrusion port configured to dispense the material;flowing the material through the extrusion port of the nozzle;engaging a tapered end of a sealing needle with the tapered inner surface of the nozzle, thereby sealing the extrusion port and stopping flow of the melted material, wherein the tapered inner surface of the nozzle has a first taper angle and the tapered end of the sealing needle has a second taper angle, and wherein the second taper angle is the same or smaller than the first taper angle; andwithdrawing the tapered end of the sealing needle, thereby resuming flow of the material through the extrusion port.31. The method of claim 30 , wherein the pharmaceutically acceptable material comprises a drug.32. The ...

DOSAGE FORMS AND USE THEREOF

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner. 129-. (canceled)30. An oral drug dosage form comprising:a) a column core having a top surface and a bottom surface, andb) a shell wrapping around the column core and leaving the top, bottom, or both surfaces exposed,wherein the shell has a slower dissolution rate than the substrate in the column core;wherein the column core comprises at least two vertical segments, each comprising a different drug embedded in a substrate, andwherein upon exposure to gastrointestinal fluid the drugs in the at least two vertical segments are simultaneously released through the exposed surface area.31. The oral drug dosage form of claim 30 , wherein the shell is water insoluble.32. The oral drug dosage form of claim 30 , wherein the substrate in each of the at least two vertical segments are the same.33. The oral drug dosage form of claim 30 , wherein the substrate in each of the at least two vertical segments are different from each other.34. The oral drug dosage form of claim 33 , wherein the drugs in the at least two different vertical segments are released at different rates.35. The oral drug dosage form of claim 30 , wherein the column core comprises at least three vertical segments.36. The oral drug dosage form of claim 35 , wherein the at least three vertical segments are pie-shaped.37. The oral drug dosage form of claim 30 , wherein only the top surface of the column core is exposed.38. The oral drug dosage form of claim 30 , wherein both the top surface and bottom surface of the column core are exposed.39. The oral drug dosage form of claim 30 , wherein the drugs in the at least two different vertical segments are released according ...

3D PRINTING METHODS FOR COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner. 2. The method of claim 1 , further comprising providing the API in a solid form and melting the API.3. The method of claim 2 , wherein the API is in a powdered form.4. The method of claim 2 , further comprising mixing the API with the first erodible material.5. The method of claim 1 , wherein the first erodible material and the second erodible material are the same.6. The method of claim 1 , wherein the first erodible material and the second erodible material are different.7. The method of claim 1 , wherein the first erodible material comprises a water-soluble thermoplastic material claim 1 , a plasticizer claim 1 , or a combination thereof.8. The method of claim 1 , wherein the second erodible material is selected from the group consisting of a water-soluble polymer claim 1 , an erodible or dissolvable polymer claim 1 , a wax claim 1 , a saccharide claim 1 , a plasticizer claim 1 , and a combination thereof.9. The method of claim 1 , wherein the substrate comprises a water-insoluble thermoplastic material.10. The method of claim 1 , wherein the API is tofacitinib.11. The method of claim 1 , further comprising providing a computer-aided 3D design of the oral dosage form for 3D printing.12. The method of claim 1 , wherein the melted substrate is deposited before the deposition of the extruded homogeneous melted mixture.13. The method of claim 1 , wherein the second erodible material is deposited after the deposition of the extruded homogenous melted mixture. This application is a continuation of U.S. patent application Ser. No. 16/402,028, filed May 2, 2019, which is a continuation of U.S. patent application Ser. No. 16/289, ...

ORAL DRUG DOSAGE FORM COMPRISING VARIOUS RELEASE PROFILES

The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner. 1. An oral drug dosage form comprising:a) a first substrate forming a first layer comprising a first drug embedded therein, andb) a second substrate forming a second layer comprising a second drug embedded therein,wherein the first layer and the second layer are stacked together,wherein upon exposure to gastrointestinal fluid the first drug is released according to a first drug release profile and the second drug is released according to a second drug release profile,wherein the first drug release profile is an immediate-release (IR) profile, andwherein the second drug release profile is an extended-release (ER) profile.2. The oral drug dosage form of claim 1 , wherein the first drug and the second drug are different.3. The oral drug dosage form of claim 1 , wherein the first drug and the second drug are the same.4. The oral drug dosage form of claim 3 , wherein the first drug and the second drug are both topiramate.5. The oral drug dosage form of claim 1 , further comprising a third substrate forming a third layer comprising a third drug embedded therein claim 1 , wherein upon exposure to gastrointestinal fluid the third drug is released according to a third drug release profile.6. The oral drug dosage form of claim 5 , wherein the third drug is different from the first drug and/or the second drug.7. The oral drug dosage form of claim 5 , wherein the third drug is the same as the first drug and/or the second drug.8. The oral drug dosage form of claim 5 , wherein the third drug release profile is different from the first drug release profile and/or the second drug release profile.9. The oral drug dosage form of claim 5 , ...

CONTROL AND PROTECTION APPARATUS FOR ELECTRIC MOTOR

A control and protection apparatus for an electric motor, comprising an inverter (), a first converter (), a temperature detection apparatus (), and a second converter (). The first converter () is used for generating, on the basis of an input signal, a first control signal to control working of the inverter (). The temperature detection apparatus () is used for detecting the temperature of the electric motor () and for acquiring a temperature signal. The second converter () is used for generating a second control signal on the basis of the temperature signal detected and for providing the second control signal to the inverter (). The inverter () is used for controlling wording of the electric motor () on the basis of the first control signal and of the second control signal. The control and protection apparatus for the electric motor is low in costs and high in safety and reliability. 1. A control and protection apparatus for an electric motor , characterized in that the control and protection apparatus for the electric motor comprises a frequency transformer , a first converter , a temperature-detection device and a second converter , wherein the first converter is configured to generate a first control signal from an input signal to control the operation of the frequency transformer , the temperature-detection device is configured to detect the temperature of the electric motor and generate a temperature signal , the second converter is configured to generate a second control signal from the temperature signal , and provide the second control signal to the frequency transformer , and the frequency transformer is configured to control the operation of the electric motor based on the first control signal and the second control signal.2. The control and protection apparatus for the electric motor according to claim 1 , wherein the frequency transformer comprises a switch tube driver and an inverter claim 1 , and the switch tube driver is configured to provide a ...

Precision pharmaceutical 3d printing device

Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

SIDE-LIGHTING LIGHT GUIDE PLATE AND BACKLIGHT MODULE

This disclosure provides a side-lighting light guide plate and a backlight module. The side-lighting light guide plate comprises a light guide component having a first light incident surface and a light emitting surface that intersects with the first light incident surface; a plurality of first light guide columns disposed on the first light incident surface to guide light into the light guide component; the light emitting surface configured to emit the light. 1. A side-lighting light guide plate , wherein the side-lighting light guide plate comprises a light guide component having a first light incident surface and a light emitting surface that intersects with the first light incident surface;a plurality of first light guide columns disposed on the first light incident surface, to guide light into the light guide component;the light emitting surface configured to emit the light.2. The side-lighting light guide plate as claimed in claim 1 , wherein the plurality of first light guide columns are perpendicular to the first light incident surface.3. The side-lighting light guide plate as claimed in claim 1 , wherein the plurality of first light guide columns are parallel to the light emitting surface and are sequentially arranged on the first light incident surface.4. The side-lighting light guide plate as claimed in claim 3 , wherein the plurality of first light guide columns are disposed along a same interval.5. The side-lighting light guide plate as claimed in claim 1 , wherein the plurality of first light guide columns are cylindrical.6. The side-lighting light guide plate as claimed in claim 5 , wherein a height of the plurality of first light guide columns is 5-10 times of a diameter of the plurality of first light guide columns.7. The side-lighting light guide plate as claimed in claim 1 , wherein the light guide component has a second light incident surface that intersects with the light emitting surface;the plurality of first light guide columns and/or a ...

DELIVERING ENHANCED ACTIVE AGENTS

The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum. 4. The method of claim 1 , further comprising selecting the active agent to have a structure selected from the group consisting of a peptide claim 1 , an oligopeptide claim 1 , a polypeptide claim 1 , a protein claim 1 , an antibody claim 1 , an oligonucleotide claim 1 , a polynucleotide claim 1 , a virus-like particle claim 1 , a small molecule claim 1 , an oligosaccharide claim 1 , an imaging agent claim 1 , and combinations thereof.5. The method of further comprising increasing the half-life of the active agent in blood serum after the administering.6. The method of further comprising reducing the immunogenicity of the active agent in blood serum after the administering.7. The method of further comprising increasing the half-life of the active agent in blood serum after the administering.8. The method of further comprising reducing the immunogenicity of the active agent in blood serum after the administering.9. The method of further comprising increasing the half-life of the active agent in blood serum after the administering.10. The method of further comprising reducing the immunogenicity of the active agent in blood serum after the administering.11. The method of further comprising increasing the half-life of the active agent in blood serum after the administering.12. The method of further comprising reducing the immunogenicity of the active agent in blood serum after the administering.13. The method of claim 1 , wherein the ...

DISPLAY SCREEN, DISPLAY DEVICE AND METHOD FOR MANUFACTURING A DISPLAY SCREEN

The present application relates to a display screen, a display device and a method for manufacturing a display screen. The display screen comprises a contour line and an active display region. The active display region includes an edge display region close to the contour line and a main display region away from the contour line. The edge display region and the contour line are intersected. The display screen includes a light-emitting layer and a light-outputting layer having a first region, the first region of the light-outputting layer has a scattering structure provided thereon. Light emitted from the light-emitting layer is deviated from an original propagation direction after passing through the scattering structure. The first region is formed into at least a partial region on the light-outputting layer corresponding to the edge display region. 1. A display screen , whereinthe display screen comprises a contour line, and an active display region,the active display region comprises an edge display region close to the contour line and a main display region away from the contour line, andthe edge display region and the contour line are intersected; andwherein the display screen comprises a light-emitting layer and a light-outputting layer having a first region,the first region of the light-outputting layer has a scattering structure provided thereon,light emitted from the light-emitting layer is deviated from an original propagation direction after passing through the scattering structure, andthe first region is formed into at least a partial region of the light-outputting layer corresponding to the edge display region.2. The display screen according to claim 1 , wherein a projection of the first region on a substrate of the display screen is a first projection claim 1 , a projection of the edge display region on the substrate of the display screen is a second projection claim 1 , and the first projection overlaps the second projection.3. The display screen ...

Enhanced sn-38 anticancer agent

The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

LIQUID CRYSTAL DISPLAY AND BACKLIGHT MODULE THEREOF

A liquid crystal display and a backlight module thereof are provided. The backlight module includes a backlight source and a light guide plate. The backlight source is disposed at a side surface of the light guide plate. The light guide plate has an accommodation section for accommodating a functional module. The backlight module includes a compensation light source that is disposed on the light guide plate. The accommodation section is located between the backlight source and the compensation light source. The backlight module includes a compensation light source, and the backlight source and the compensation light source are located at two opposite sides of the accommodation section. The compensation light source may compensate for the illumination light in the light guide plate blocked by the functional module, so as to solve the non-uniform display problem of blocking the illumination light from the backlight source by the functional module. 1. A backlight module comprising a backlight source and a light guide plate , wherein the backlight source is disposed at a side surface of the light guide plate , the light guide plate has an accommodation section for accommodating a functional module , the backlight module further comprises a compensation light source that is disposed on the light guide plate , and the accommodation section is located between the backlight source and the compensation light source.2. The backlight module according to claim 1 , wherein the compensation light source comprises a flexible circuit board and one or more light emitting diode (LED) lamps that are disposed on the flexible circuit board claim 1 , the light guide plate has a mounting section for accommodating the one or more LED lamps claim 1 , and the flexible circuit board leans against a bottom surface of the light guide plate.3. The backlight module according to claim 2 , wherein a side of the flexible circuit board toward the accommodation section coincides with an edge of the ...

Controlled release dosage form

The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

Copolymer of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives

A new polymer, the feed monomers and molar percents of which, exclusive of a polymerization initiator and crosslinker, are: A. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 16 mole % of an additional vinylic copolymerizable monomer; B. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 21 mole % up to less than 42 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 29 mole % of an additional vinylic copolymerizable monomer, or C. (I) 16 mole % up to less than 42 mole % of a siloxy silane of formula I, (II) 42 mole % of 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 36 mole % of an additional vinylic copolymerizable monomer, where formula I is ##STR1## where formula II is ##STR2## where Group A is a vinylic acid or a (meth)acrylate as defined herein. Methods of manufacture of the polymer and the use thereof as a pressure adhesive, especially a transdermal and/or transmucosal delivery system pressure sensitive adhesive, are also claimed.

Copolymer of (meth)acryloxy-alkyl-siloxysilane and alkyl(meth)acrylates and the use thereof as pressure sensitive adhesives

A new polymer, the feed monomers and molar percents of which, exclusive of a polymerization initiator and crosslinker, are: A. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 16 mole % of an additional vinylic copolymerizable monomer; B. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 21 mole % up to less than 42 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 29 mole % of an additional vinylic copolymerizable monomer; or C. (I) 16 mole % up to less than 42 mole % of a siloxy silane of formula I, (II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 36 mole % of an additional vinylic copolymerizable monomer; where formula I is ##STR1## where formula II is ##STR2## in which R 3 is hydrogen or methyl; and R 4 is methyl or a linear or branched chain C 2-10 alkyl which is unsubstituted; where Group A is (meth)acrylic acid, maleic acid, fumaric acid, itaconic acid, itaconic acid, cinnamic acid, crotonic acid, fumaric acid, maleic acid, 2-(methy)acroyloxyethyl sulfonic acid, 2-(meth)acrylamido-2-methylpropane sulfonic acid, vinyl sulfonic acid, p-styrene sulfonioc acid, allyl sulfonic acid or of formula III.

Polymer prepared from silanyl-silyloxy-alkyl(meth)acrylate and alkyl(meth)acrylate monomers and optionally other minor amounts of other monomers

A new polymer has a polymerisation feed mixt. of (a) a polymerisation initiator, (G) 0-5 mole.% based on the total of all monomers, present, of a vinylic copolymerisation crosslinker, and (c) one of the following mixt. (i) or (iii) where (i) is (I), 42-58 mole % of siloxy silane of formula (I), (II) 42-58 mole % of an unsubstd. alkyl (meth)acrylate of formula (II), (III) 0-5 mole % of a Gp. A monomer, and (IV) 0-16 mole % of an additional vinylic copolymerisable monomer of Gp. B, or where (iii) is (I) 16-42 mole % of siloxysilane I, (II) 42-58 mole % of alkyl (meth)acrylate II, (III) 0-5 mole % of a Gp A monomer and (IV) 0-36 mole % of a Gp B monomer. In the formulae, R1 = H or CH3; R2 = 1-6C alkylene; n = 0-2; R3 = H or CH3; R4 = CH3 or linear or branched 2-10C unsubstd. alkyl. Gp. A monomers are (meth)acrylic acid, maleic acid, fumaric acid, itaconic acid, cinnamic acid, crotonic acid, 2-(meth)acryloxyloxyethyl sulphonic acid, 2-(meth) acrylamido -2-methylpropane sulphonic acid, vinyl sulphonic acid, p-styrene sulphonic acid, allyl sulphonic acid and monomers of the formula (III). (R5 = H or CH3; R6 = 1-10C linear or branched alkyl, opt. substd. by CH, 1-4C alkoxy, Cl, Br, F, CO2H, 1-4C alkoxycarbonyl, 1-4C alkylcarbonyloxy or NH2). Gp. B monomer is neither a polymerisation inhibitor, a cross-linker nor a cpd. of formula (I) or (II) nor a Gp A monomer, but is a mono-satd. monomer copolymerisable with (I), (II) or Gp A cpds.

Controlled release dosage form

The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

Dosage forms and use thereof

Multi-chamber tire manufacturing mold

A multi-chamber tire manufacturing mold, comprising an upper holding plate (11) and a lower holding plate (13) having an interval between the upper holding plate (11) and the lower holding plate (14); a tire periphery forming slider (16), a tire inner chamber forming slider (17), an upper mold block (121), a lower mold block (122), and a central mold post (18) are arranged in the interval; the upper holding plate (11) is connected to the plurality of upper mold blocks (121), and the lower holding plate (13) is connected to a plurality of lower mold blocks (122), forming an enclosed chamber (10); the tire inner chamber forming slider (17) is arranged in the enclosed chamber (10), forming a flexible portion chamber (101) and a partitioned chambers (171), such that a plurality of isolating chambers (25) are formed in the flexible portion (21); the openings of the isolating chambers (25) together with the tire periphery forming slider (16) form an enclosed chamber via process sealing members and fill the forming outer body (22). A tire flexible portion manufactured by the mold is provided with a plurality of enclosed isolating chambers, and can withstand multiple punctures and still meet the demands of high-speed run, thus the service life and performance of the tire are improved.

Dosage forms of controlled release at specific gastrointestinal sites

A dosage form of controlled release at specific gastrointestinal sites is provided. The dosage form includes a shell defining a first and a second compartment, a first active pharmaceutical ingredient (API) loaded in the first compartment, and a second API loaded in the second compartment, wherein the first API and the second API can be the same or different. The shell includes a first material soluble in a first gastrointestinal site and a second material soluble in a second gastrointestinal site.

Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life

Identity authentication by using human biological characteristic

A human biological characteristic file corresponding to a particular identity is received and used as a base file. A characteristic code to be authenticated is obtained according to a human biological characteristic of a person who requests identity authentication when an identity authentication request corresponding to the particular identity is received. A base characteristic code is collected from a base file. A collecting algorithm applied for collecting the base characteristic code is the same as or matches an algorithm applied for obtaining the characteristic code. The present techniques determine whether the base characteristic code and the characteristic code correspond to a same human biological characteristic. If a result is positive, the identity authentication request is verified. The present techniques implement communication between different terminal devices of different manufacturers and effectively improve user experiences, thereby efficiently and conveniently implementing remote identity authentication.

Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life

A delivery system for active agents, and methods of making and using the systems, are provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.

System and method for intelligent circuit breaking in adjustable speed drives

CHOLESTERIC REGULATING COMPLEX OF SIRT1 AND LXR AND ITS USE

Delayed sustained-release oral drug dosage forms of a janus kinase (jak) inhibitor and methods of use thereof

Provided are delayed sustained-release oral drug dosage forms comprising a Janus kinase (JAK) inhibitor, such as tofacitinib. In other aspects, provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of treatment and/or prevention associated with the oral drug dosage forms described herein.

Controlled release dosage form

The present invention generally relates to a pharmaceutical dosage form and controlled release of biologically active agents, diagnostic agents, reagents, cosmetic agents, and agricultural/insecticide agents. In one embodiment, the dosage form has a substrate that forms a compartment, wherein the substrate includes at least a first piece and a second piece, wherein the first piece operably links to the second piece. The dosage form contains a drug content that is loaded into the compartment. The dosage form also has a releaser operably linked to the substrate which upon contact with water or body fluid is capable of separating the first and second piece to open the compartment and release the drug content.

Multi-chamber tire manufacturing mold

Un molde (1) de fabricación de neumáticos multicámara que comprende una placa superior (11) de sujeción y una placa inferior (12) de sujeción; la placa superior (11) de sujeción y la placa inferior (12) de sujeción están dispuestas alternativamente y en paralelo entre sí con intervalos entre la placa superior (11) de sujeción y la placa inferior (12) de sujeción; una pluralidad de deslizadores (16) que forman la periferia del neumático, bloques (121) del molde superior, bloques (122) del molde inferior y postes centrales (18) de molde están dispuestos en los intervalos; los deslizadores (16) que forman la periferia del neumático están dispuestos a lo largo de la dirección de altura de los intervalos, y la pluralidad de deslizadores (16) que forman la periferia del neumático están conectados en orden y dispuestos de forma anular; los postes centrales (18) del molde están dispuestos a lo largo de la dirección de la altura de los intervalos de manera anular, y ubicados en un lado interno de la pluralidad de deslizadores (16) que forman la periferia del neumático, y dispuestos alternativamente con la pluralidad de deslizadores (16) que forman la periferia del neumático; el poste central (18) del molde está configurado en el interior con una parte (19) de formación que está dispuesta alrededor del poste central (18) del molde; un extremo inferior de la placa superior (11) de sujeción está conectado con una pluralidad de bloques (121) del molde superior que están dispuestos en un círculo; se forma una cámara cerrada entre la pluralidad de bloques (121) del molde superior, la pluralidad de bloques (122) del molde inferior, las partes (19) de formación y la pluralidad de deslizadores (16) que forman la periferia del neumático; la cámara está provista en su interior con una pluralidad de deslizadores (17) que forman la cámara interna del neumático, que están conectados en orden dispuestos alrededor de la cámara; el deslizador (17) que forma la cámara interior del neumático ...

High-precision additive manufacturing device and high-throughput additive manufacturing system

The present disclosure generally relates to an additive manufacturing system. The system can comprise a material supply module for melting and pressurizing a printing material; a micro-screw printing head comprising: a micro-screw comprising a threaded stem portion and a conical head portion, wherein the threaded stem portion is threaded throughout its length for volume measurement; a sleeve, and a nozzle, wherein a distal end of the nozzle comprises: a conical inner surface, and an outlet port for dispensing the print material, wherein the conical inner surface of the nozzle is configured to be in contact with the conical head portion of the micro-screw to stop dispensing the printing material at the nozzle when the micro-screw printing head is in a closed position; a driving module comprising: a rotation motor for driving a rotating motion of the micro-screw, and an actuator for driving a vertical motion of the micro-screw.

Light-transmissive display panel, display panel and display apparatus

The present application provides a light-transmitting display panel, display panel and display apparatus. The light-transmitting display panel includes a first pixel array including a first minimum repeating unit. The first minimum repeating unit includes at least one light-transmitting column unit. The at least one light-transmitting column unit has a central axis parallel to an extending direction of the at least one light-transmitting column unit. The at least one light-transmitting column unit includes a plurality of first sub-pixels spaced apart from one another in the extending direction of the at least one light-transmitting column unit, wherein at least one of the first sub-pixels in the at least one light-transmitting column unit is set to deviate from the central axis. According to the light-transmitting display panel of embodiments of the present application, photosensitive components may be integrated on the back of the light-transmitting display panel, to achieve under-screen integration of the photosensitive components such as cameras, while the light-transmitting display panel can display pictures, so as to achieve a full-screen design in which the light-transmitting display panel is applied to a display apparatus.

System and method for intelligent circuit breaking in adjustable speed drives

An ASD circuit includes an input, solid-state switch rectifier bridge, DC link, and DC link capacitor bank. A pre-charge circuit is coupled between the input and the DC link capacitor bank and includes pre-charge relays operable in an on state that allows the AC power input to power the rectifier bridge during a normal operating state and an off state that allows the AC power input to pre-charge the DC link capacitor bank through a pre- charge resistor of the pre-charge circuit during a pre-charge operating state. A protection relay of a protection circuit is coupled between the pre-charge relays and the DC link capacitor bank, the protection relay operable in an on state that prevents the pre-charge circuit from connecting to the DC link capacitor bank when a capacitor short circuit occurs and an off state that allows the pre-charge circuit to electrically connect to the DC link capacitor bank.

一种工程管理咨询用演示装置

本实用新型公开了一种工程管理咨询用演示装置，包括底座，万向轮，主面板所述底座的内腔两侧均设置有螺纹杆，所述螺纹杆的顶部贯穿底座的顶部内表壁并延伸至外部，所述螺纹杆的底部套接有副锥齿，所述底座的底部内表壁通过螺栓固定安装有双轴驱动电机，所述双轴驱动电机的输出轴均套接有主锥齿，所述主面板的后端面设置有螺纹块。本实用新型中，通过双轴驱动电机、螺纹杆、螺纹块的设置，利用驱动电机带动螺纹杆旋转，螺纹杆转动的同时使套设在螺纹杆外的螺纹块上下移动，从而带动主面板上下运动，实现了主面板的高度调节。

Methods of designing an oral drug dosage form based on a target pk profile and dosage forms thereof

Method and system for creating pharamceutical products by additive manufacturing

Provided are pharmaceutical products manufactured using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of the pharmaceutical product.

Display panel

A display panel includes a first display region with multiple light-transmitting sub-pixels and multiple non-light-transmitting sub-pixels. The multiple light-transmitting sub-pixels and the multiple non-light-transmitting sub-pixels are arranged in a preset pixel arrangement structure in the first display region. The multiple non-light-transmitting sub-pixels are randomly arranged in at least one set region of the first display region.

Method and system for creating pharamceutical products by additive manufacturing

Cholesterinregulierender komplex aus sirt1 und lxr und seine verwendung

Gastroretentive pharmaceutical dosage form

A pharmaceutical dosage form, comprising: a pharmaceutical unit which includes a drug, at least one unfolding member, and a retaining member, wherein the unfolding member is connected to the pharmaceutical unit, and is constructed to have a contracted shape, which makes the unfolding member become closer the pharmaceutical unit, and an unfolding shape, which makes the unfolding member become farther away from the pharmaceutical unit; the retaining member is connected to the at least one unfolding member, and applies a constraint force to the at least one unfolding member, so as to make the unfolding member be in the contracted shape; and the retaining member contains a water-soluble material, and is constructed to remove the constraint force from the unfolding member when the water-soluble material is dissolved, such that the at least one unfolding member can change from the contracted shape to the unfolding shape.

Methods of designing an oral drug dosage form based on a target pk profile and dosage forms thereof

Drug dosage forms for stomach retention

Provided herein are drug dosage forms having a swellable component, which alone or in conjugation with one or more other components of the drug dosage forms expand the overall size of the drug dosage form in the stomach. The drug dosage forms are configured to be retained in the stomach for an extended period of time based on this increase in size of the drug dosage form in the stomach (e.g., retained in the stomach for a period of at least about 24 hours). The drug dosage forms described herein are formulated to release a drug during at least a portion of the stomach residency period. In other aspects, also provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of delivering a drug to an individual, wherein such methods are associated with the drug dosage forms described herein.

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or a reagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or a reagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Oral drug dosage forms having a desired pk profile and methods of designing and producing thereof

Dosage forms with desired release profiles and methods of designing and making thereof

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or a reagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Dosage forms with desired release profiles and methods of designing and making thereof

In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or a reagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Dosage forms with desired release profiles and methods of designing and making thereof

Dosage forms of controlled release at specific gastrointestinal sites

A dosage form of controlled release at specific gastrointestinal sites is provided. The dosage form includes a shell defining a first and a second compartment, a first active phamaecutical ingredient (API) loaded in the first compartment, and a second API loaded in the second compartment, wherein the first API and the second API can be the same or different. The shell includes a first material soluble in a first gastrointestinal site and a second material soluble in a second gastrointestinal site.

Fremgangsmåde og systemer til frembringelse af farmaceutiske produkter gennem fremstilling af tilsætningsstof

Delayed sustained-release oral drug dosage forms of a janus kinase (jak) inhibitor and methods of use

Provided are delayed sustained-release oral drug dosage forms comprising a Janus kinase (JAK) inhibitor, such as tofacitinib. In other aspects, provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of treatment and/or prevention associated with the oral drug dosage forms described herein.

Oral drug dosage forms for stomach retention

Provided herein are drug dosage forms designed to provide a desired retention in an individual based on geometric differences between a pre-administration and post-administration state of the dosage form. In certain aspects, provided are oral drug dosage forms comprising a swellable and expandable material configured, upon swelling or expanding, to drive expansion of the overall size of the oral drug dosage forms such that the oral drug dosage forms are retained in the stomach for a desired period of time. In certain other aspects, provided is directed to components useful for the oral drug dosage forms taught herein. In certain other aspects, provided is directed to methods of designing, methods of making, such as involving three-dimensional (3D) printing, injection molding, ultrasonic welding, or any combination thereof, commercial batches, and methods of delivering a drug to an individual comprising administering an oral drug dosage form taught herein.

一种纤维与沥青材料粘结强度测试装置

本实用新型公开了一种纤维与沥青材料粘结强度测试装置，包括试件制备部分和拉伸测试部分；试件制备部分包括支架、底座和沥青基槽，沥青基槽的轴心处开设有中心孔，纤维穿过中心孔伸入底座的空腔中，纤维的上端设置固定件，下端设置一配重件；拉伸测试部分包括万能试验机和盛样皿，纤维穿过盛样皿的开孔。本实用新型的有益效果是，测试装置结构简单，便于制作与操作，试件制作精度高；通过拉拔试验可测出不同纤维与沥青胶浆间的粘结强度，便于找出与沥青粘结效果最好的纤维；从纤维与沥青基体的粘结性能的角度出发，通过测定纤维与沥青胶浆的粘结强度实现了对路用纤维的评价和选型。

Cancer detection model and construction method therefor, and reagent kit

A cancer detection model and a construction method therefor, and a reagent kit, relating to the technical field of cancer detection. The method comprises: performing whole genome sequencing on plasma free DNA to mine nucleosome distribution features, terminal sequence features, and fragment size distribution features that can be applied to cancer detection; constructing classification models of the three indicators to obtain prediction scores of each indicator for a sample; then integrating these scores using a logistic regression model, and adding copy number variation feature information to obtain an ultimate classification and prediction model. The cancer detection model significantly improves the efficiency and accuracy of cancer detection, requires a small amount of data for analysis, has low detection cost, can detect different cancers, and is applicable for analyzing and predicting tumors in various stages. In addition, the reagent kit can complete the detection of the indicators required by the detection model, such that the reagent kit can be innovatively applied in ctDNA detection in the field of cancers.

Display panel, display apparatus, and display panel forming method

The present application relates to a display panel, a display device and a forming method of the display panel. The display panel includes a first region, and the display panel includes: a substrate; a light-emitting device layer stacked on the substrate, wherein the light-emitting device layer includes a plurality of first light-emitting devices distributed in an array in the first region, and wherein the first light-emitting device includes a first electrode, a particle unit disposed at least partially in a same layer with the first electrode and surrounding the first electrode, a first light-emitting module located on the first electrode, and a second electrode located on the first light-emitting module; wherein the particle unit includes a glue layer and a plurality of particles distributed within the glue layer, an orthographic projection of at least part of one particle of at least part of the particles on the substrate does not completely overlap with an orthographic projection of the first electrode on the substrate. The display panel provided by the present application can meet the requirements for full screen display, while reducing the impact of the diffraction phenomenon on the imaging effect of the devices such as front cameras.

Display panel, display apparatus, and display panel forming method

Display panel, display device, and forming method of display panel

A display panel, a display device and a forming method of the display panel. The display panel includes a first region, and the display panel includes: a substrate; a light-emitting device layer stacked on the substrate. The light-emitting device layer includes a plurality of first light-emitting devices distributed in an array in the first region, and the first light-emitting device includes a first electrode, a particle unit disposed at least partially in a same layer with the first electrode and surrounding the first electrode, a first light-emitting module located on the first electrode, and a second electrode located on the first light-emitting module. The particle unit includes a glue layer and a plurality of particles distributed within the glue layer.

Delayed sustained-release oral drug dosage forms of a janus kinase (jak) inhibitor and methods of use thereof

Provided are delayed sustained-release oral drug dosage forms comprising a Janus kinase (JAK) inhibitor, such as tofacitinib. In other aspects, provided are methods of designing, methods of making, such as using three-dimensional printing, and methods of treatment and/or prevention associated with the oral drug dosage forms described herein.